- Home
- HNRG vs TNGX Comparison
HNRG vs TNGX Comparison
Compare HNRG & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- TNGX
- Stock Information
- Founded
- HNRG 1949
- TNGX 2014
- Country
- HNRG United States
- TNGX United States
- Employees
- HNRG N/A
- TNGX N/A
- Industry
- HNRG Coal Mining
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- HNRG Energy
- TNGX Health Care
- Exchange
- HNRG Nasdaq
- TNGX Nasdaq
- Market Cap
- HNRG 698.9M
- TNGX 723.2M
- IPO Year
- HNRG N/A
- TNGX N/A
- Fundamental
- Price
- HNRG $18.63
- TNGX $7.62
- Analyst Decision
- HNRG Buy
- TNGX Strong Buy
- Analyst Count
- HNRG 3
- TNGX 6
- Target Price
- HNRG $19.00
- TNGX $10.00
- AVG Volume (30 Days)
- HNRG 492.6K
- TNGX 1.5M
- Earning Date
- HNRG 11-11-2025
- TNGX 11-05-2025
- Dividend Yield
- HNRG N/A
- TNGX N/A
- EPS Growth
- HNRG N/A
- TNGX N/A
- EPS
- HNRG N/A
- TNGX N/A
- Revenue
- HNRG $419,451,000.00
- TNGX $24,296,000.00
- Revenue This Year
- HNRG $8.52
- TNGX $20.42
- Revenue Next Year
- HNRG $4.46
- TNGX N/A
- P/E Ratio
- HNRG N/A
- TNGX N/A
- Revenue Growth
- HNRG N/A
- TNGX N/A
- 52 Week Low
- HNRG $6.34
- TNGX $1.03
- 52 Week High
- HNRG $22.01
- TNGX $9.84
- Technical
- Relative Strength Index (RSI)
- HNRG 62.32
- TNGX 63.92
- Support Level
- HNRG $16.89
- TNGX $6.38
- Resistance Level
- HNRG $18.99
- TNGX $6.90
- Average True Range (ATR)
- HNRG 0.68
- TNGX 0.45
- MACD
- HNRG 0.23
- TNGX 0.05
- Stochastic Oscillator
- HNRG 87.63
- TNGX 80.12
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.